Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Protagenic Therapeutics Inc (PTIXW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/23/2026: PTIXW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.38 | 52 Weeks Range 0.00 - 0.24 | Updated Date 05/24/2025 |
52 Weeks Range 0.00 - 0.24 | Updated Date 05/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -189.6% | Return on Equity (TTM) -512.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 491613 |
Shares Outstanding - | Shares Floating 491613 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Protagenic Therapeutics Inc
Company Overview
History and Background
Protagenic Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer. The company was founded in 2018. Its primary focus is on leveraging its proprietary platform to develop therapies that target specific cancer types. Significant milestones include advancing its lead candidate into clinical trials.
Core Business Areas
- Oncology Immunotherapy Development: Protagenic Therapeutics Inc. is dedicated to the discovery, development, and commercialization of novel immunotherapies for the treatment of cancer. Their platform aims to identify and activate T-cell responses against tumor-specific antigens.
Leadership and Structure
Protagenic Therapeutics Inc. is led by a management team with experience in drug development and biotechnology. Specific details on the current leadership and organizational structure would require access to the company's latest filings and investor relations information.
Top Products and Market Share
Key Offerings
- PTG-100: PTG-100 is Protagenic Therapeutics Inc.'s lead drug candidate, an immunotherapy designed to treat various types of cancer. As a clinical-stage product, it does not currently have market share data. Its competitors include companies developing other forms of immunotherapy, such as checkpoint inhibitors and CAR-T therapies, from major pharmaceutical and biotechnology firms like Merck, Bristol Myers Squibb, and Pfizer.
Market Dynamics
Industry Overview
The oncology immunotherapy market is a rapidly growing and highly competitive sector within the pharmaceutical industry. Driven by advancements in understanding the immune system's role in cancer, companies are investing heavily in developing novel therapies to improve patient outcomes. Key trends include personalized medicine, combination therapies, and targeting previously 'undruggable' cancer targets.
Positioning
Protagenic Therapeutics Inc. is positioned as a niche player in the early-stage development of novel immunotherapies. Their competitive advantage lies in their proprietary platform and focus on specific cancer indications, aiming to offer differentiated therapeutic options.
Total Addressable Market (TAM)
The Total Addressable Market for cancer immunotherapies is in the hundreds of billions of dollars globally and continues to expand. Protagenic Therapeutics Inc. is positioned to address a segment of this TAM with its targeted therapies, but its current market penetration is minimal due to its clinical-stage status.
Upturn SWOT Analysis
Strengths
- Proprietary technology platform for immunotherapy development.
- Focus on novel targets potentially leading to differentiated therapies.
- Experienced management team in drug development.
Weaknesses
- Clinical-stage company with no approved products.
- Dependence on successful clinical trial outcomes.
- Limited financial resources compared to larger biopharmaceutical companies.
- Reliance on external funding.
Opportunities
- Growing demand for effective cancer treatments.
- Potential for strategic partnerships with larger pharmaceutical companies.
- Expansion into new cancer indications.
- Advancements in genetic sequencing and biomarker identification.
Threats
- High failure rate in clinical trials.
- Intense competition in the oncology space.
- Regulatory hurdles and lengthy approval processes.
- Pricing pressures and reimbursement challenges.
Competitors and Market Share
Key Competitors
- Merck & Co., Inc. (MRK)
- Bristol Myers Squibb Company (BMY)
- Pfizer Inc. (PFE)
Competitive Landscape
Protagenic Therapeutics Inc. operates in a highly competitive landscape dominated by large pharmaceutical companies with established R&D infrastructure and commercial capabilities. Its advantage lies in its specific therapeutic approach and potential to target unmet needs. However, it faces significant challenges in R&D, regulatory approval, and market penetration against established players.
Growth Trajectory and Initiatives
Historical Growth: Protagenic Therapeutics Inc.'s historical growth has been characterized by the advancement of its drug development pipeline and the expansion of its research capabilities. Financial growth, in terms of revenue, has been minimal or absent.
Future Projections: Future growth projections for Protagenic Therapeutics Inc. are heavily dependent on the successful progression of its clinical candidates through regulatory approval. Analyst estimates, if available, would focus on potential peak sales of future products and the overall market opportunity.
Recent Initiatives: Recent initiatives likely include advancing its lead drug candidate into further clinical trial phases, forging strategic collaborations, and seeking additional funding to support its development pipeline.
Summary
Protagenic Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies. While it possesses a promising proprietary platform and a dedicated leadership team, its key weaknesses lie in its lack of approved products, dependence on clinical trial success, and limited financial resources. The company's growth hinges on successful progression through clinical trials and potential strategic partnerships in a highly competitive market. It needs to carefully manage its R&D expenditures and secure adequate funding to navigate the challenging drug development process.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Financial news outlets
- Industry reports
Disclaimers:
This analysis is based on publicly available information and should not be considered investment advice. Stock market performance is subject to various risks and uncertainties. Investors should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Protagenic Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2021-04-27 | President, CEO & Director Mr. Barrett Evans | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1 | Website https://www.protagenic.com |
Full time employees 1 | Website https://www.protagenic.com | ||
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.